Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in anIn VitroModel of Invasive Pulmonary Aspergillosis

Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints

(2012) Adam R. Jeans et al.   JOURNAL OF INFECTIOUS DISEASES

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Earlier Response Assessment in Invasive Aspergillosis Based on the Kinetics of Serum Aspergillus Galactomannan: Proposal for a New Definition

(2011) S. A. Nouer et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy

(2011) Susan J. Howard et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis

(2010) J. M. Lestner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

(2010) R Herbrecht et al.   BONE MARROW TRANSPLANTATION

Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis

(2010) S. Koo et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Therapy for fungal diseases: opportunities and priorities

(2010) David W. Denning et al.   TRENDS IN MICROBIOLOGY

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

(2009) V. Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin

(2009) W. W. J. van de Sande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients

(2009) Johan Maertens et al.   CANCER

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

(2009) C. Viscoli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions

(2008) S. Perkhofer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Strong Correlation between Serum Aspergillus Galactomannan Index and Outcome of Aspergillosis in Patients with Hematological Cancer: Clinical and Research Implications

(2008) Marisa H. Miceli et al.   CLINICAL INFECTIOUS DISEASES

EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds

(2008)   CLINICAL MICROBIOLOGY AND INFECTION

Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism

(2008) Eveline Snelders et al.   PLOS MEDICINE